Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in NNOX.
← Back to Free Index

NNOX

Analysis as of: 2026-11-07
Nano-X Imaging Ltd.
Nanox develops digital tomographic X-ray systems and sells related cloud workflow, teleradiology, AI imaging, and health IT services.
ai cloud healthcare medical devices software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Funding Gate Before Imaging Flywheel
This is a distressed medtech platform with real assets but a funding bottleneck. If it funds activations and proves reimbursed scan volume, today’s near-cash valuation can re-rate sharply; if not, dilution can consume the upside.

Analysis

Thesis
Nanox is a distressed but real option on turning a cleared low-cost imaging device plus workflow, remote reading, and health IT stack into a recurring community-imaging utility; if it funds activations and proves reimbursed scan volume before dilution overwhelms holders, 2031 equity value can compound non-linearly from today’s near-cash base.
Last Economy Alignment
AI and remote workflow should expand low-cost imaging demand, and Nanox captures value through regulated hardware plus usage-based services. The catch is that bigger incumbents can still out-bundle it before the installed-base flywheel forms.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
54.7x (from 5 most recent analyses)
Reasoning
This is a survival-to-proof re-rating story. If liquidity is secured, more deployed systems become active paid-scan sites, and each scan pulls through workflow, reading, and health IT revenue, the business can graduate from distressed optionality to a small recurring imaging utility. I still cap the upside by valuing it as a mixed medtech-services stack rather than a pure software company.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
This is a sequence-risk equity. Nanox first needs financing flexibility and listing continuity, then liquidity, then proof that active sites produce repeat reimbursed scan volume with better contribution margins. The upside is large because the starting value is distressed; the danger is that dilution and slow activation consume the economics before the flywheel shows up.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.31
It owns a cleared imaging device and the workflow that turns scans into reports and revenue, so AI can deepen usage once more sites go live. The danger is that bigger imaging vendors can bundle similar tools while limited cash delays the installed-base flywheel.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$4.13
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case